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Key Points 
 TSCM are abundant early after allogeneic hematopoietic stem cell transplantation and derive 
from naive T cells that survived pt-Cy. 
 Pt-Cy allows the generation of donor primary and recall responses in transplanted patients, 
even in the presence of persistent antigen. 
Abstract 
Early T-cell reconstitution following allogeneic transplantation depends on the persistence and 
function of T cells that are adoptively transferred with the graft. Posttransplant cyclophosphamide 
(pt-Cy) effectively prevents alloreactive responses from unmanipulated grafts, but its effect on 
subsequent immune reconstitution remains undetermined. Here, we show that T memory stem cells 
(TSCM), which demonstrated superior reconstitution capacity in preclinical models, are the most 
abundant circulating T-cell population in the early days following haploidentical transplantation 
combined with pt-Cy and precede the expansion of effector cells. Transferred naive, but not TSCM or 
conventional memory cells preferentially survive cyclophosphamide, thus suggesting that 
posttransplant TSCM originate from naive precursors. Moreover, donor naive T cells specific for 
exogenous and self/tumor antigens persist in the host and contribute to peripheral reconstitution by 
differentiating into effectors. Similarly, pathogen-specific memory T cells generate detectable recall 
responses, but only in the presence of the cognate antigen. We thus define the cellular basis of T-
cell reconstitution following pt-Cy at the antigen-specific level and propose to explore naive-
derived TSCM in the clinical setting to overcome immunodeficiency. These trials were registered at 
www.clinicaltrials.gov as #NCT02049424 and #NCT02049580. 
Introduction 
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a potentially curative approach 
for blood cancers. Patients benefit from the graft-versus-tumor effect exerted by alloreactive T cells, 
although, at the same time, they may suffer from graft-versus-host disease (GVHD), especially in 
the context of T-replete transplantations. Immunosuppressants are, unfortunately, not selective for 
alloreactive T cells and may thus limit adaptive immune responses to opportunistic infections and 
cancer.
1
 Depletion of T cells from the allograft prevents GVHD but results in delayed reconstitution 
and increased morbidity and mortality due to opportunistic infections and tumor relapse.
2
 High-dose 
cyclophosphamide given early posttransplant (pt-Cy) has been proposed to selectively spare 
bystander naive and memory T cells while depleting alloreactive T cells in vivo after infusion of 
unmanipulated grafts.
3⇓⇓⇓⇓-8 Indeed, the latter are thought to proliferate quickly in the alloantigen-
replenished environment, thus becoming susceptible to pt-Cy, while the former survive and promote 
reconstitution.
9
 
In the first months, immune competence is in part restored in a thymus-independent fashion by 
proliferation of the T cells in response to increased levels of homeostatic cytokines or exogenous 
antigens.
1,10
 Production of new T cells occurs only later by resumed thymic output.
10
 The 
unmanipulated graft contains subsets of naive and memory T cells with defined specificities that 
display distinct proliferative and persistence capacities in response to lymphopenia.
11,12
 In 
particular, a population of early-differentiated human memory T cells with stem cell–like properties 
(the T memory stem cells [TSCM]) has been reported to preferentially reconstitute immunodeficient 
mice compared with more differentiated central memory (TCM) and effector memory (TEM) T 
cells.
13
 A recent study suggested that the posttransplant lymphopenic environment may favor the 
generation of TSCM from naive precursors.
14
 Nevertheless, naive or TSCM cells are relatively absent 
early after transplantation,
3,15⇓-17 thus rendering unclear to what extent these T-cell subsets 
contribute to reconstitution. The persistence and expansion of the transferred T cells would confer 
protection toward opportunistic infections and cancer. In this regard, whether pt-Cy differentially 
affects donor T-cell subsets at the polyclonal and antigen-specific levels remains undetermined. 
Materials and methods 
Patients and transplantation procedures 
Thirty-nine consecutive patients were treated according to the haploidentical hematopoietic stem 
cell transplantation (haplo-HSCT) protocol established by Luznik et al.
4
 All experiments display 
biological replicates from different patients or healthy donors who were randomly selected, unless 
specified (such as for the study of antigen-specific responses). Details about the transplantation 
procedure are available in supplemental Methods (available on the Blood Web site). Patient 
characteristics are listed in supplemental Table 1. Patients and donors signed consent forms in 
accordance with the Declaration of Helsinki. Clinical and experimental protocols were approved by 
the institutional review board of Humanitas Research Hospital and Istituto Nazionale Tumori. 
Flow cytometry and cell sorting 
Monoclonal antibodies (described in supplemental Methods) were purchased from BD Biosciences 
and BioLegend, unless specified otherwise, or conjugated in-house (http://www.drmr.com/abcon). 
Frozen cells were thawed and prepared for flow cytometry as described previously.
18
 Chemokine 
receptor expression was revealed by incubating cells at 37°C for 20 minutes. The Cytofix/Cytoperm 
kit (BD Biosciences) was used to detect intracellular Ki-67.
19
 T-cell subsets were defined as 
depicted in supplemental Figure 1B and as described in supplemental Methods. Cells were stained 
for 15 minutes at room temperature with Aqua viability dye (Life Technologies). Samples were 
acquired on a Fortessa flow cytometer or separated via a FACS Aria (all from BD Biosciences). 
Absolute lymphocyte numbers were obtained from the Humanitas Cancer Center. 
Cell stimulations and treatments 
Cells were seeded at 0.25 × 10
6
 cells/mL. Cell proliferation was determined by the analysis of 5-
(and 6)-carboxyfluorescein diacetate succinimidyl ester (CFSE; used at 5 μM; Life Technologies) 
dilution. Cells were stained at 37°C for 7 minutes, washed in complete medium, and stimulated 
with rhIL-15 (Peprotech) for 8 to 10 days. Patient peripheral blood mononuclear cells (PBMCs) at 
different times post–haplo-HSCT (n = 5; day 41, day 53, day 56, day 57, and day 65) are shown in 
Figure 2D. 
To induce cytokine production, PBMCs (final volume, 200 μL) were stimulated with phorbol 12-
myristate 13-acetate (PMA; 10 ng/mL) and ionomycin (500 ng/mL) (both from Sigma Aldrich) for 
4 hours in the presence of GolgiPlug (BD Biosciences), as described previously.
19
 To detect 
antigen-specific T cells by intracellular cytokine staining, PBMCs were stimulated for 16 hours 
with a cytomegalovirus (CMV) pp65 peptide pool (15-mer peptides overlapping by 11; JPT 
Technologies; 1 μg/mL per peptide) or with VAXIGRIP seasonal influenza vaccine (Sanofi; 1:40 
vol/vol). Intracellular cytokine production was revealed as described previously.
19
 
In mixed lymphocyte reaction cultures, highly purified naive T cells (TN) and memory T cells were 
cultured at 1:1 ratio with major histocompatibility complex (MHC)-mismatched antigen-presenting 
cells (allo-APCs) or autologous APCs (auto-APCs) (both sorted as CD3
−
CD56
−
 mononuclear cells). 
To block APC:T-cell interaction, anti-MHC class I and class II antibodies were used (clones G46-
2.6 and Tu39, respectively; 10 μg/mL). Nonalloreactive T cells were identified by gating either on 
CFSE
hi
 cells or on CD25
−
CD69
−
 cells. 
Enumeration of antigen-specific T cells by MHC class I tetramers 
The peptide:MHC class I tetramers used in the study are described in supplemental Methods. 
Staining was conducted at 37°C for 15 minutes. To detect Wilms tumor 1 (WT1)-positive cells, 
tetramers recognizing 3 different WT1 epitopes were combined. CD8
+
 T cells were enriched by 
negative magnetic sorting (STEMCELL Technologies) from 10 to 30 × 10
6
 PBMCs prior to 
staining. Between 0.3 and 3 × 10
6
 CD8
+
 T cells were acquired. For MART-1 and WT1, the percent 
threshold of positivity (0.003926 and 0.003705, respectively) was set as the 75th percentile of 
distributions resulting from the percentage of tetramer-binding cells in CD4
+
 T cells. Only 1 
representative threshold is depicted in Figure 4D for simplicity. 
Clonotypic analysis of antigen-specific T cells 
Preliminary peptide mapping experiments were conducted to identify donor and recipient CMV-
specific T cells responding to the same pool of 12 peptides, as described previously.
20
 
Aqua
−
CD14
−
CD3
+
CD4/CD8
+
 T cells producing interferon-γ (IFN-γ) or tumor necrosis factor (TNF) 
were sorted into 1.5-mL tubes (Sarstedt; median of sorted cells, 3901; range, 712-30 030). 
Clonotypic composition was determined using a DNA-based multiplex polymerase chain reaction 
for TCRB gene rearrangements.
21
 
Analysis of donor chimerism 
Donor chimerism was determined by polymerase chain reaction analysis of short tandem repeats as 
described previously.
22
 
Statistical analysis 
Analysis was performed using GraphPad PRISM (6.0b) and SPICE 5.22 software.
23
 The 
nonparametric paired Wilcoxon rank test and unpaired Mann-Whitney test were used to compare 2 
groups. Differences in the pie-chart distributions were calculated with SPICE software using a 
permutation test. P values are 2 sided and were considered significant when ≤.05. 
Results 
T-cell dynamics following haplo-HSCT 
We first evaluated the reconstitution patterns of major T-cell subsets. The characteristics of the 
patients included in the study, discussed in a previous publication,
5
 are shown in supplemental 
Table 1. Absolute counts at specific time points up to 1 year after haplo-HSCT (supplemental 
Figure 1A) are reported in supplemental Figure 2A. Counts of total T cells were undetectable in 
most of the patients up to 6 weeks post–haplo-HSCT. Rapid increases were observed from week 6, 
when mycophenolate mofetil was discontinued, and were followed by equally rapid declines at 
week 9. These declines were possibly caused by the apoptotic loss of highly activated effector 
cells.
24
 Subsequently, T cells progressively recovered over time (supplemental Figure 2A). A flow 
cytometry panel detecting naive and memory subsets (supplemental Figure 1B) revealed that 
recovering T cells predominantly displayed a transitional memory (TTM), TEM, or terminal effector 
(TTE) phenotype (supplemental Figures 2B and 3). These dynamics paralleled the proliferation (ie, 
Ki-67
+
) of multiple subsets (supplemental Figure 4). Single-cell analysis of the mismatched HLA in 
circulating CD3
+
 (supplemental Figure 2C) or chimerism analysis of sorted CD4
+
 and CD8
+
 T cells 
(supplemental Figure 2D) confirmed donor-dependent T-cell reconstitution, as previously reported.
5
 
Pt-Cy preferentially depletes proliferating effector/memory T cells 
To gain insights into the mechanisms of pt-Cy effect on naive and memory cells, we analyzed the 
T-cell compartment within a few days following transplantation. Cyclophosphamide (Cy) 
preferentially depletes proliferating cells. We collected peripheral blood (PB) before (day 3) and 
after pt-Cy (ie, at day 7). The vast majority of CD3
+
 T cells at day 3 expressed markers of 
proliferation (Ki-67) and activation (HLA-DR; Figure 1A). In vivo treatment with Cy depleted 
proliferating cells (Figure 1A), thereby indicating that Ki-67 is a surrogate marker of Cy 
susceptibility. In healthy individuals, Ki-67 is preferentially expressed by memory-phenotype T 
cells.
11
 Combined analysis of Ki-67 expression and naive and memory markers (supplemental 
Figure 1B) revealed that Ki-67 expression was confined to memory subsets while both CD4
+
 and 
CD8
+
 TN were almost exclusively Ki-67
−
 (Figure 1B). Similar trends were confirmed by gating on 
donor-derived T cells, as identified by the mismatched HLA (supplemental Figure 5A). Overall, 
CD4
+
 proliferated less compared with CD8
+
 T cells (Figure 1B), hence resulting in their preferential 
accumulation following pt-Cy (Figure 1C). Similar to conventional CD4
+
 T cells, circulating 
CD4
+
CD25
+
CD127
−
 regulatory T (TREG) cells (supplemental Figure 5B) with a naive phenotype (ie, 
CD45RO
−
CCR7
+
CD45RA
+
; supplemental Figure 5C-D) increased following pt-Cy (supplemental 
Figure 5C), presumably due to their lower proliferation compared with memory cells at day 3 
(supplemental Figure 5E). Overall, TREG tended to express lower Ki-67 levels than conventional 
CD4
+
 T cells (supplemental Figure 5E and Figure 1B, respectively), suggesting that they are 
preferentially spared by pt-Cy in vivo, as recently reported in vitro.
25
 
 
 
 
 
Figure 1  
Pt-Cy preferentially depletes proliferating effector/memory T cells. (A) Representative (out of 
10) Ki-67 and HLA-DR expression in PB CD3
+
 T cells at day 3 and day 7 post–haplo-HSCT. (B) 
Mean ± standard error of the mean (SEM) frequency (n = 22; each dot represents a patient) of Ki-
67
+
 T cells with a given differentiation phenotype at day 3 post–haplo-HSCT. +P < .05 vs TRTE; *P 
< .05 vs TN; Wilcoxon test. (C) Mean ± SEM frequency (n = 23) of CD4
+
 and CD8
+
 T cells at day 3 
and day 7 post–haplo-HSCT. P < .05 vs day 3; Wilcoxon test. (D) CFSE dilution and CD25 
expression by TN and TMEM following incubation with auto-APCs or allo-APCs for 3 days. The gate 
in black identifies CFSE
lo
 proliferating (ie, alloreactive) cells, whereas that in gray CFSE
hi
 
nonproliferating cells. (E) CD45RO expression by CFSE
lo
 and CFSE
hi
 cells, identified as in panel 
D, originally sorted as TN (top) or TMEM (bottom). 
It has been shown that alloreactive T cells preferentially derive from CD45RA
+
 TN.
26,27
 The 
preferential expression of Ki-67 by donor memory T cells and their subsequent depletion therefore 
seems counterintuitive. Moreover, it has been proposed that memory cells are relative resistant to 
Cy treatment.
3,25
 To better clarify these aspects, we incubated highly purified naive or memory T 
cells with allo-APCs or control auto-APCs. T-cell activation induces the rapid loss of CD45RA and 
the upregulation of CD45RO, thereby suggesting that the Ki-67
+
 memory fraction at day 3 (Figure 
1B) also contains allogeneic cells from the TN pool. Incubation of CD4
+
 TN or CD45RO
+
 memory T 
(TMEM) cells with allo-APCs, but not auto-APCs, for 3 days led to the proliferation (CFSE dilution) 
and upregulation of CD25 in a fraction of T cells (Figure 1D), indicating that alloreactivity resides 
in both subsets. CFSE
lo
 cells from TN, originally fluorescence-activated cell sorter (FACS) sorted as 
CD45RO
−
, uniformly upregulated CD45RO compared with CFSE
hi
 cells (Figure 1E). These results 
indicate that the Cy-sensitive Ki-67
+
 fraction at day 3, exclusively identified by memory 
phenotypes, contains cells originating from both TN and memory T cells. 
Donor TSCM cells dominate the peripheral T cell compartment following pt-Cy 
Next, we investigated the events occurring in the circulation following pt-Cy. Given that only donor 
T cells are responsible for peripheral reconstitution, we analyzed the composition of the donor and 
recipient T cells by using HLA-specific antibodies in suitable patients. Although recipient T cells 
were preferentially memory (with some differences between the CD4
+
 and CD8
+
 T cells in terms of 
TCM, TEM, and TTE distribution; Figure 2A-B), including activated (HLA-DR
+
) and senescent 
(CD57
+
) cells
11
 (Figure 2A), donor cells predominantly expressed markers of naivety as well as 
CD95, thus resembling TSCM (Figure 2A-B).
11,13
 Notably, the frequencies of TSCM among the donor 
populations largely exceeded those observed in the bone marrow (BM; Figure 2B) and in the PB of 
donors (typically 2% to 3% of total T cells).
13
 These TSCM were present also in the following weeks 
post–haplo-HSCT but were gradually replaced by more differentiated TCM and TEM (supplemental 
Figure 6). 
 
 Figure 2  
Donor TSCM dominate the peripheral T-cell compartment following pt-Cy. (A) FACS analysis 
of PB T cells at day 7 post–haplo-HSCT. Donor (D; red) and recipient (R; dark gray) cells are 
identified by an antibody recognizing the mismatched HLA-A*02. Light-gray cells in the 
background are T cells from the PB of a healthy donor. (B) Median ± SEM frequency of D and R T 
cells (identified as in panel A) with a given differentiation phenotype in patients at day 7 post–
haplo-HSCT (n = 7, CD4
+
; n = 6, CD8
+
). Only donor-recipient pairs whose mismatched HLA could 
be investigated by flow cytometry are included. *P < .05 vs day 7 D cells; Mann-Whitney test. (C) 
Percent CFSE
lo
 CD8
+
 T cell subsets from a healthy donor (HD) and a recipient (R) at day 41 post–
haplo-HSCT after PBMC culture with 1 (gray, serving as a nonproliferating control) or 50 ng/mL 
IL-15 (black) for 8 days. N/D, not detected. (D) Mean ± SEM CFSE
lo
 CD8
+
 T-cell subsets 
(calculated as in panel C) from healthy donors (n = 6) and haplo-HSCT patients (n = 5). TMEM, 
CD45RO
+
 memory T cells. *P < .05, Mann-Whitney test. (E) Combinations of IFN-γ, IL-2, and 
TNF production in gated TSCM from patients (n = 3) and in T-cell subsets from healthy donors (HD; 
n = 4). *P < .05, permutation test. 
We next investigated whether the TSCM-phenotype cells observed posttransplant also acquired TSCM 
functional features, ie, the capability to respond to interleukin-15 (IL-15; for CD8
+
) and to produce 
effector cytokines following stimulation with PMA/ionomycin (for both CD4
+
 and CD8
+
). These 
assays allow to differentiate them from “true” TN.
13
 We first attempted to do this in T cells isolated 
at day 7. However, the cells failed to survive or were unresponsive in vitro (not shown), presumably 
due to exposure to immunosuppressive drugs in vivo. Moreover, these cells could not be purified by 
FACS sorting ex vivo due to their paucity; therefore, bulk PBMC cultures were used. T-cell 
phenotypes are largely maintained following IL-15
13
 and PMA/ionomycin treatment (supplemental 
Figure 7), thus justifying our approach. CD8
+
 TSCM between day 41 and day 65 post–haplo-HSCT 
diluted CFSE similarly to CD45RO
+
 TMEM. Conversely, in line with previous experiments, TN from 
healthy donors did not (Figure 2C-D). Moreover, TSCM displayed a combination of IFN-γ, IL-2, and 
TNF expression similar to that of naturally occurring TSCM following PMA/ionomycin stimulation 
but distinct from the functional profiles of TN and TMEM from healthy donors (Figure 2E). This 
combination is reminiscent of the functionality of TSCM in nonhuman primates.
28
 Collectively, these 
data show that T cells with the TSCM phenotype are abundant following pt-Cy and display TSCM 
functional properties. 
Putative TN-cell origin of posttransplant TSCM 
The loss of TN and the accumulation of TSCM at day 7 was unexpected, given the preferential 
survival of TN, but not of TSCM, to pt-Cy. Moreover, TSCM were almost absent in the graft (Figure 
2B). We thus reasoned that posttransplant TSCM-phenotype cells might have derived from 
transferred TN. To validate this concept, we followed the expression of CD31, a marker 
preferentially expressed by early-differentiated CD4
+
 TRTE
29
 and downregulated in CD4
+
 TSCM and 
TMEM.
13
 CD8
+
 T cells were not studied in this regard, as CD31 has no phenotypic value in the 
identification of CD8
+
 TRTE. Before transplantation (day 0), CD45RO
−
CCR7
+
 naive-like (NL; ie, 
comprising both TN and TSCM) T cells were virtually absent in the PB of the recipient but were 
detected at day 3 (Figure 3A). Host T cells did not display the NL phenotype at multiple time points 
(Figure 2A-B and data not shown), thus obviating the need to differentiate between donor and 
recipient HLA to follow this population of cells. NL-CD4
+
 T cells from BM were mostly CD95
−
 
but progressively acquired CD95 within both the CD31
+
 and the CD31
−
 fractions (Figure 3B). This 
shift was independent of pt-Cy, as in vitro mafosfamide treatment did not induce CD95 in FACS-
sorted TN (not shown). At day 7, CD95
+
 TSCM expressed CD31 at frequencies similar to those of the 
CD95
−
 fraction and higher than those of TSCM from the PB of the related donors (Figure 3B-C). 
These CD31
+
CD95
+
 cells are normally present, although at low frequency, in the PB of healthy 
donors (Figure 3B), indicating that they are not an artifact of allo-HSCT. Importantly, CD95 
expression increased specifically in NL cells between day 3 and day 7 (Figure 3D), thus excluding 
that CD95 upregulation is a generalized effect of all T cells. Furthermore, in vitro incubation of TN 
with allo-APCs, but not auto-APCs, led to CD95 upregulation in the nonalloreactive fraction 
(defined as negative for both CD25 and CD69 activation markers; Figure 3E-F), indicating that 
acquisition of the TSCM phenotype may occur in the allogeneic environment. Such an increase could 
be prevented by anti-MHC class II (for CD4
+
) and class I (for CD8
+
) blocking antibodies (Figure 
3E-F). It could be argued that CD31 is induced by preexisting TSCM upon activation and/or 
proliferation. To test this possibility, we cocultured FACS-sorted CD31
+
 TRTE as well as CD31
−
 TN 
and TMEM (supplemental Figure 8) with allo-APCs to monitor CD31 expression in the proliferating 
(CFSE
lo
) population. CD31
+
 TSCM could not be tested due to low recovery. TRTE lost CD31 
expression upon CFSE dilution (Figure 3G). Accordingly, CD31
−
 subsets failed to reacquire CD31 
(Figure 3G). Collectively, our results suggest that TSCM observed following pt-Cy putatively derive 
from adoptively transferred TN. 
 
 Figure 3  
Putative TN-cell origin of posttransplant TSCM. (A) Representative frequency (out of 12) of 
CD45RO
−
CCR7
+
 T cells in a patient a day 0 and day 3 post–haplo-HSCT. (B) Representative (out 
of 12) CD31 and CD95 expression on NL-CD4
+
 T cells from the PB and BM of a donor and from 
the PB of the related recipient at different times post–haplo-HSCT. A scheme with the 
nomenclature of subsets according to phenotype is depicted on the left. NL, CD45RO
−
CCR7
+
. 
Numbers in plots indicate the percentage of cells in the gates. (C) Mean ± SEM CD31 expression 
on PB CD4
+
CD95
−
 cells and CD4
+
 TSCM from marrow donors (D) and CD4
+
 TSCM from the related 
recipients (R; n = 12) at day 7 post–haplo-HSCT. *P < .05 vs D TSCM; Wilcoxon test. (D) Fold 
change in CD95 median fluorescence intensity (MFI) in different T-cell subsets (n = 19) between 
day 3 and day 7. *P < .05 vs NL; Wilcoxon-paired test. (E) Representative analysis of CD95 
expression by TN cells following incubation with different stimuli. Histograms are referred to the 
CD25
−
CD69
−
 nonalloreactive population, as specified in the text. (F) Summary of the data obtained 
in panel E (n = 8; 4 independent experiments; *P < .05 vs allo-APCs, Wilcoxon-paired test). (G) 
CFSE dilution and CD31 expression by FACS-sorted T-cell subsets following incubation with allo-
APCs for 5 days. D, donor; R, recipient. 
 
Persistence and memory differentiation of antigen-specific TN 
Next, we addressed whether donor TN that survived pt-Cy contribute to reconstitution at the 
antigen-specific level. We followed the fate of self-/tumor-specific T cells by using MHC class I 
tetramers. The staining specificity is shown in supplemental Figure 9A. We confined our analysis to 
∼90 days post–haplo-HSCT to exclude the generation of new TN by resumed thymic output.
10
 CD4
+
 
TRTE or TN were absent during this time period (supplemental Figure 3). Accordingly, signal-joint 
T-cell receptor excision circles (indicative of thymic output) in PB lymphocytes from an 
independent cohort of patients receiving haplo-HSCT and pt-Cy but myeloablative conditioning 
were much lower at 3 and 6 months post–haplo-HSCT compared with donor samples (B.B., 
unpublished observation). Antigen-specific CD8
+
 T cells were present at similar frequencies in the 
BM and PB of donors (supplemental Figure 9B), as described previously,
30
 thus justifying the use 
of PB cells when patient BM was unavailable. Two CMV
+
 patients receiving CMV
−
 grafts mounted 
CMV-specific CD8
+
 T-cell responses (Figure 4A), suggesting that CMV reactivation and, thus, 
activation and depletion of transferred CMV-specific T cells do not occur within 4 days post–haplo-
HSCT. These CMV-specific responses are thought to originate from the transferred TN and not 
from preexisting memory cells, as CD8
+
 T cells, different from CD4
+
 T cells,
31
 were shown to lack 
pathogen-specific memory T cells in unexposed individuals.
32
 TN specific for self/tumor antigens, 
such as MART-1 and WT1, behaved similarly. These specific cells, which are present at relatively 
high frequencies in healthy individuals,
33,34
 mostly displayed a TN phenotype in healthy donors 
(Figure 4B-C). In the recipients, they could be detected up to day 90 post-HSCT (Figure 4D) and 
acquired a CD45RO
+
CCR7
−
CD95
+
 phenotype (as soon as day 45 post–haplo-HSCT for MART-1), 
thus suggesting effector/memory differentiation (Figure 4B-C). We conclude that antigen-specific 
TN survive pt-Cy and participate in immune reconstitution in the lymphopenic host. 
 
 Figure 4  
Persistence and memory differentiation of antigen-specific TN. (A) Frequency of CD8
+
 T cells 
in PBMCs from 2 CMV
−
 donors and matched CMV
+
 recipients at different time points post–haplo-
HSCT. (B) Frequency and phenotype of MART-1– and WT1-specific CD8+ T cells identified by 
MHC class I tetramers. Tetramer
+
 T cells are overlaid on top of the total CD8
+
 T-cell population 
depicted in gray. In panels A and B, numbers indicate the percentage of cells identified by the gates. 
(C) Frequency of MART-1
+
 (filled gray circles) and WT1
+
 (blank circles) CD8
+
 T cells with a TN-
cell phenotype in donors (D) and recipients (R) at day 45 and day 90 post–haplo-HSCT. P < .05, 
Mann-Whitney test. (D) Mean ± SEM frequency of the cells identified in panel B. 
Antigen-specific memory T cells may survive pt-Cy and expand in the host in the 
presence of the cognate antigen 
Antigen-specific memory can be transferred with allo-HSCT.
35
 We sought to test whether persistent 
antigen in the recipient may render antigen-specific T cells susceptible to pt-Cy, as reported in 
murine models.
36
 To this end, we investigated PB CD4
+
 and CD8
+
 CMV-specific T cells in 
donor/recipient pairs who were matched for CMV infection (Figure 5A). These cells were of donor 
origin, as indicated by the analysis of the mismatched HLA-A*02 (Figure 5B). FACS sorting of the 
same cells followed by sequencing of the TCRB gene revealed that some CDR3 sequences 
overlapped between donor and recipients in most of the patients at the amino acid (Figure 5C-D) 
and nucleotide levels (data not shown) while the majority appeared to be unique, hence 
corroborating the idea that some antigen-specific T-cell clones may survive pt-Cy and expand in the 
recipient in the presence of the cognate antigen. 
 
Figure 5  
Antigen-specific memory T cells may survive pt-Cy and expand in the host in the presence of 
the cognate antigen. (A) Frequency of CMV-specific memory T cells in haplo-HSCT recipients 
(R) at day 45 and day 90 and in related donors (D). (B) Representative analysis of donor-derived 
CMV-specific T-cell responses detected by simultaneous analysis of the mismatched HLA (in this 
case the donor was HLA-A*02
−
) and intracellular IFN-γ following stimulation with CMV pp65 
overlapping peptide mix. Plots show Aqua
−
CD3
+
 cells. (C-D) TCRB clonal composition of CMV-
specific CD4
+
 (C) and CD8
+
 (D) T cells in CMV
+/+
 donor/recipient pairs. Overlapping sequences 
are highlighted in gray. d, day after haplo-HSCT. 
Poor expansion of adoptively transferred memory T cells in the absence of 
cognate antigen 
Finally, we determined the extent of reconstitution of adoptively transferred memory T cells in the 
virtual absence of cognate antigen. Flu-specific memory CD8
+
 T cells were detectable in the PB and 
BM of donors, but not in the recipients, up to 90 days post–haplo-HSCT (Figure 6A-C; 
supplemental Figure 9B). Interestingly, CD3
+
 natural killer T cells recognizing the α-
galactosylceramide analog PBS57 declined as well. The specific cells were Ki-67
−
 at the time of 
transfer (supplemental Figure 9C). Similarly, adoptively transferred CMV-specific CD4
+
 and CD8
+
 
T cells from a CMV
+
 donor could not be detected in a CMV
−
 recipient (Figure 6B-C), as previously 
reported.
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 Flu-specific CD4
+
 T cells responding in vitro to the seasonal influenza vaccine (Flu
VAX
) 
behaved in the same way (Figure 6C). It has been demonstrated that early-differentiated memory T 
cells better persist and expand in vivo following adoptive transfer.
12,35
 In our setting, the relative 
abundance of the different memory T-cell phenotypes did not influence such behaviors (Figure 6D). 
These results indicate that adoptively transferred memory T cells fail to expand in the blood of 
recipients in the absence of their cognate antigen. 
 
 
Figure 6  
Poor expansion of adoptively transferred memory T cells in the absence of cognate antigen. 
(A) MHC class I tetramer identification of CD8
+
 T cells specific for Flu IK9 and Flu GL9 epitopes 
in the PB of marrow donors and the related recipients (R) at day 90 post–haplo-HSCT. (B) TNF and 
IFN-γ production by CD4+ and CD8+ T cells from the haplo-HSCT #10 donor/recipient pair (CMV+ 
and CMV
−
, respectively) following in vitro stimulation with CMV pp65 peptide pool. In panels A 
and B, numbers indicate the percentage of cells identified by the gates. (C) Summary of the 
frequency of CD3
+
 natural killer T cells binding CD1d/PBS57 tetramer and Flu and CMV-specific 
CD4
+
 and CD8
+
 T cells from the PB of donor (D) and the related recipients (R) at day (d) 45 and 
d90 post–haplo-HSCT. *P < .05, Mann-Whitney test. (D) Differentiation phenotypes of the 
transferred antigen-specific T cells identified in panel C. Data are presented relative to total 
memory T cells. 
Discussion 
Here, we report the cellular mechanisms responsible for T-cell reconstitution following haplo-
HSCT and pt-Cy at the antigen-specific and clonal levels and suggest that “TN-derived TSCM” play a 
nonredundant role in this regard. A proposed model of the events occurring in this type of HSCT is 
depicted in Figure 7. Extensive phenotypic and functional analysis of T-cell subsets during the first 
few days following transplantation revealed that nonalloreactive TN were preferentially spared by 
pt-Cy because of their delayed activation kinetics. Unexpectedly, TN were outnumbered by TSCM-
phenotype cells at day 7, which later displayed TSCM functional properties. Conversely, as much as 
70% of memory/effector-phenotype T cells were proliferating by day 3 post–haplo-HSCT and were 
subsequently depleted by pt-Cy. Experiments performed in mouse models by Mayumi et al showed 
that pt-Cy failed to block GVHD following transfer of allogeneic donor splenocytes immunized 
with host T cells 7 days before,
8
 thus leading to the hypothesis that memory T cells are more 
resistant to pt-Cy compared with TN.
3
 However, because day 7 coincides with the effector phase (ie, 
the peak of T-cell expansion), escape from pt-Cy possibly occurred because of the relative 
abundance of transferred effectors rather than the acquisition of memory capacity. Our experiments 
show that both TN and memory T cells divide in response to allogeneic stimulation and that TN 
rapidly acquire CD45RO, thus indicating that the proliferating memory/effector-phenotype cells 
observed at day 3 include T cells derived from both compartments (Figure 1). 
 
 
Figure 7  
Proposed model of the cellular mechanisms leading to T-cell reconstitution following haplo-
HSCT and pt-Cy. Naive (TN) and memory T cells (TMEM) are infused in the recipient with the BM. 
Allogeneic antigens (allo-Ags), as well as inflammatory/homeostatic cytokines, the availability of 
which increases after chemotherapy, induce T-cell activation. Proliferating (HLA-DR
+
, Ki-67
+
) T 
cells uniformly acquire an effector phenotype, irrespective of their original differentiation status, 
and are preferentially depleted by Cy, given at day 3 and 4 after HSCT. T stem cell memory (TSCM) 
is the dominant peripheral T-cell subset at day 7, likely originating from TN that survived Cy. In the 
following weeks, naive-derived TSCM generate memory cells in response to exogenous antigens and, 
presumably, homeostatic cytokines. Adoptively transferred TMEM, which have survived Cy, expand 
to detectable levels in the circulation only in the presence of the cognate antigen. Whether T-cell 
memory can persist in the haplo-HSCT individual in the absence of the cognate antigen is currently 
unknown. 
TSCM-phenotype cells were the dominant donor T cells in the PB following pt-Cy and are thought to 
derive from donor TN. A weakness of the current study is that this relationship could not be 
demonstrated directly at the antigen-specific or clonal level due to the low abundance of these cells 
in vivo. Nevertheless, the experiments shown in Figure 3 support this conclusion. Although only 
circulating T cells could be tested for ethical reasons, proliferation of preexisting donor TSCM or 
redistribution from lymphoid tissues seems unlikely, given the depletion of proliferating cells by pt-
Cy and the virtual absence of TSCM in the BM, respectively. The frequency of CD45RA
+
CCR7
+
 TN 
(which are closely related to TSCM) in the transfer product positively correlated with CAR
+
 T-cell 
expansion in patients with cancer.
38
 Moreover, IL-7 and IL-15, which are elevated in lymphopenic 
individuals, favored the generation of TSCM from TN precursors,
14
 further supporting the conclusion 
that posttransplant TSCM in haplo-HSCT derive from TN. 
The acquisition of memory/effector phenotypes by self-/tumor-specific T cells also suggests that 
transferred TN progressed through an early TSCM stage (Figure 7). Self-specific memory T cells are 
rarely observed, unless in pathological conditions. For instance, MART-1–specific memory cells 
are abundant in metastatic melanoma but rare in healthy donors,
13,39
 suggesting that high antigen 
load, costimulation, and local inflammation are required for MART-1–specific T-cell priming.40 
Alternatively, the conversion of TN into memory-like cells has been reported to occur in mice in 
response to lymphopenia (ie, increased levels of homeostatic cytokines).
41⇓⇓-44 Whether homeostatic 
proliferation rather than cognate antigen stimulation is the major mechanism driving the 
differentiation of self-/tumor-specific TN will require further study. 
Although still present after Cy treatment, residual memory T cells displayed a limited reconstitution 
capacity, at least in the circulation (Figure 6). The presence of the cognate antigen seems to dictate 
the expansion of antigen-specific memory T cells, as (some) donor clones were detected in CMV-
infection–matched transplants. These data, along with those obtained from donor CMV−/recipient 
CMV
+
 transplants, imply that reactivation of CMV, and possibly of any other persistent infection, 
occurs late enough to allow pathogen-specific T cells to escape pt-Cy–mediated depletion, hence 
promoting the transfer of immunity. Nevertheless, the depletion of some nonalloreactive memory T-
cell clones by pt-Cy, caused by their more rapid homeostatic proliferation compared with TN,
13,45
 
cannot be completely ruled out. Whether T-cell memory can persist in these individuals in the 
relative absence of cognate antigen in body sites other than the circulation remains an open 
question. The current study could not test this possibility due to ethical reasons. 
Collectively, our results shed light on the mechanisms governing pt-Cy function in vivo and suggest 
that transferred TN may acquire TSCM traits in the lymphopenic environment and subsequently 
contribute to immune reconstitution. Intriguingly, the abundance of TN in BM correlated with 
improved overall survival and decreased acute GVHD.
46
 At the antigen-specific level, pt-Cy allows 
the generation of primary and memory T-cell responses even in the presence of persistent antigen in 
the host. We propose to explore the adoptive transfer of large numbers of TN before pt-Cy to favor 
the generation of TSCM and boost immune reconstitution. 
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